Mounjaro vs Zepbound: Two Names for Tirzepatide

Eli Lilly's dual GIP/GLP-1 agonist is sold under two brand names — one for diabetes, one for obesity. Here's how they compare.

Take the Free Quiz

Free consultation · No commitment · Results in weeks

Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Mounjaro vs Zepbound is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated March 2026Medically reviewed by licensed providers

Mounjaro vs Zepbound: both are FDA-approved GLP-1 medications for weight loss. Mounjaro (tirzepatide) and Zepbound (tirzepatide) differ in mechanism and clinical efficacy. Weight Method offers both from $297/month with virtual consultations and licensed providers.

Overview

Mounjaro and Zepbound are both once-weekly injectable pens manufactured by Eli Lilly containing tirzepatide, the first dual GIP and GLP-1 receptor agonist. Mounjaro received FDA approval in 2022 for type 2 diabetes, while Zepbound was approved in 2023 specifically for chronic weight management. Both use the same dose range (2.5-15 mg) and identical injection devices — the distinction is purely regulatory and affects how doctors prescribe them and how insurers cover them.

Key Fact

Mounjaro and Zepbound are both tirzepatide by Eli Lilly. Mounjaro: approved for type 2 diabetes (May 2022). Zepbound: approved for weight management (November 2023). Same molecule, same dosing (2.5-15mg weekly), different FDA indications.

Source: FDA approval data

Mounjaro

ManufacturerEli Lilly
Active Ingredienttirzepatide
FDA IndicationType 2 diabetes
FDA Approval2022
FormulationInjectable pen
FrequencyOnce weekly
Available Doses2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg
Avg. Weight Loss15-21%
Our Price$349/mo

Zepbound

ManufacturerEli Lilly
Active Ingredienttirzepatide
FDA IndicationChronic weight management
FDA Approval2023
FormulationInjectable pen
FrequencyOnce weekly
Available Doses2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg
Avg. Weight Loss20-25%
Our Price$349/mo

Key Differences

Despite containing the same molecule at the same doses, the clinical trial data differs by indication. Mounjaro's diabetes trials (SURPASS) showed 15-21% weight loss as a secondary outcome, while Zepbound's obesity trials (SURMOUNT) demonstrated 20-25% average weight loss — among the highest ever recorded for a pharmaceutical intervention. Insurance dynamics mirror the Ozempic/Wegovy split: diabetes coverage for Mounjaro is more accessible than obesity coverage for Zepbound. Both are available through Weight Method at $349/mo.

Verdict

For patients with type 2 diabetes, Mounjaro offers exceptional glucose control with industry-leading weight loss as a bonus. For patients whose primary goal is weight loss without diabetes, Zepbound is the FDA-approved option backed by the strongest obesity trial data available. Weight Method provides both at $349/mo through a streamlined online consultation.

Ready to Get Started?

Answer a few quick questions to see if you qualify for GLP-1 medication.

Check Eligibility

Your Treatment Options

Clinically proven GLP-1 medications at transparent prices

Starting at$297/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Same active ingredient as Ozempic® & Wegovy®. Proven to reduce body weight by up to 15%.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Same active ingredient as Mounjaro® & Zepbound®. Dual-action GLP-1/GIP for enhanced results.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Yes, both contain tirzepatide made by Eli Lilly and use the same dosing range (2.5-15 mg). The difference is their FDA-approved indication: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. They are marketed and prescribed as separate products.

Zepbound's dedicated obesity trials showed slightly higher average weight loss (20-25%) compared to what was observed in Mounjaro's diabetes trials (15-21%), likely because the obesity trials enrolled patients without diabetes and focused specifically on weight outcomes. The medication itself is identical.

The list prices are comparable, but real-world costs differ based on insurance. Mounjaro has broader formulary coverage for diabetes, while Zepbound faces the same limited obesity drug coverage that affects all weight management medications. Through Weight Method, compounded tirzepatide is $349/mo regardless of indication.

Doctors can prescribe Mounjaro off-label for weight loss, though it is only FDA-approved for type 2 diabetes. This is a common practice, particularly when insurance covers Mounjaro but not Zepbound. Your provider will determine the most appropriate prescription based on your health profile.

Tirzepatide (Mounjaro/Zepbound) is a dual GIP and GLP-1 receptor agonist, while semaglutide (Ozempic/Wegovy) targets only the GLP-1 receptor. This dual mechanism appears to produce greater weight loss and comparable or better glucose control. Head-to-head trials show tirzepatide outperforming semaglutide for both weight loss and A1C reduction.

Ready to Get Started?

Take our 2-minute quiz to see if you qualify for GLP-1 treatment.

Start Quiz

Free consultation. No commitment.

Related Brand Pages

Mounjaro HubMounjaro Side EffectsMounjaro ResultsMounjaro DosingZepbound HubZepbound Side EffectsZepbound ResultsZepbound Dosing

More Comparisons

Ozempic vs WegovyRybelsus vs Oral-wegovyOzempic vs MounjaroWegovy vs ZepboundOzempic vs ZepboundWegovy vs Mounjaro